

SHEFFIELD PHARMACEUTICALS INC

Form 8-K

November 07, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 7,  
2006

Sheffield Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

01-12584  
(Commission File Number)

13-3808303  
(IRS Employer Identification Number)

3985 Research Park Drive  
Ann Arbor, MI 48108  
(Address of Principal Executive Offices)

(734) 332-7800  
(Registrant's Telephone Number, Including Area Code)

N/A  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

// Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

// Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

// Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

// Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01**

**Other Events.**

On November 7, 2006, the Registrant issued the attached press release announcing that Coprexa<sup>®</sup> pivotal clinical trial results were presented at NIH-Sponsored Wilson's Disease Association Conference.

**Item 9.01**

**Financial Statements and Exhibits**

Exhibits

Exhibit 99.1 Press Release

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHEFFIELD PHARMACEUTICALS, INC.

Dated: November 7, 2006

By: /s/ Steve H. Kanzer  
Steve H. Kanzer  
Chief Executive Officer

---

EXHIBIT INDEX

Exhibit No.	Exhibit	Page
-------------	---------	------

99.1	Press Release	4
------	---------------	---

---